3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Malignant Solid Neoplasm
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
107
Radiotherapy
60
Radiation
28
Bevacizumab
19
Magnetic Resonance Spectroscopy
16
Nivolumab
15
Surgical Procedures, Operative
12
Irinotecan
11
Cyclophosphamide
10
Specimen Handling
9
Chemotherapy, Adjuvant
9
Radiotherapy, Intensity-Modulated
8
Radiosurgery
8
O(6)-benzylguanine
8
Carmustine
8
poly ICLC
7
pembrolizumab
7
motexafin gadolinium
7
fludarabine
7
Leukapheresis
7
Flucytosine
7
sargramostim
6
Radiotherapy, Conformal
6
Erlotinib Hydrochloride
6
Lomustine
5
Ipilimumab
5
Imiquimod
5
Imatinib Mesylate
5
Hydroxyurea
5
Granulocyte-Macrophage Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Glioblastoma
×
Ferrosoferric Oxide
×
Clear all
NCT04900792
2025-12-03
XACT-Fe-GBM-01
University of Iowa
Phase 1
Active not recruiting
17 enrolled